Jun 18, 2013
The Hartford Courant
Exclusive: Japan's Astellas looks to sell dermatology assets - sources
Japanese drugmaker Astellas Pharma Inc is looking to sell its dermatology portfolio, which could be worth between $500 million and $1 billion, according to three people familiar with the situation.
153 new drugs to be covered through Pharmacare
Specific drugs include Brilinta for reducing the risk of heart attack, Mezavant for treatment of ulcerative colitis and Crohn's disease, and Protopic for the treatment of moderate to severe eczema.
Sequential oral, topical tacrolimus benefits dermatitis
Sequential therapy with oral tacrolimus and topical tacrolimus may be an effective treatment for severe atopic dermatitis , according to a pilot study published in the October issue of the Journal of the American Academy of Dermatology .
Tacrolimus - Key patent, SPC, and data exclusivity expiry (7 country...
This Pipeline Selector report covers Tacrolimus Tacrolimus indications: Immunosuppressant; Eczema Tacrolimus innovator: Fujisawa ; Janssen-Cilag Examples of information found in this online report include: - Includes key patent publications for 7 countries - Contains SPC protection for every EU state plus patent term extensions in other countries - ... (more)